Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ENPP2 | Q13822 | 7/20 | 0.60 |
| ▸ | LPL | P06858 | 2/20 | 0.54 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.54 |
| ▸ | NOS1 | P29475 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | PRMT6 | Q96LA8 | 6/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.44 |
| ▸ | MGLL | Q99685 | 1/20 | 0.42 |
| ▸ | HTR7 | P34969 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5872608 | 0.81 | ENPP2 (0.72) | ENPP2LPLLIPGKDM4EALDH1A1 | |
| SCHEMBL25880865 | 0.81 | ENPP2 (0.60) | ENPP2LPLLIPGKDM4EALDH1A1 | |
| SCHEMBL15981401 | 0.80 | ENPP2 (0.55) | ENPP2LPLLIPGKDM4EALDH1A1 | |
| SCHEMBL6352816 | 0.79 | ENPP2 (0.58) | ENPP2LPLLIPGKDM4EMAPT | |
| SCHEMBL955708 | 0.79 | ENPP2 (0.53) | ENPP2LPLLIPG | |
| SCHEMBL1697126 | 0.79 | MAPT (0.64) | NOS1KDM4ECYP3A4MAPTPRMT6 | |
| SCHEMBL692342 | 0.78 | ENPP2 (0.67) | ENPP2LPLLIPGKDM4EALDH1A1 | |
| SCHEMBL6358240 | 0.78 | ENPP2 (0.51) | ENPP2LPLLIPGKDM4EMAPT | |
| SCHEMBL532278 | 0.78 | ENPP2 (0.51) | ENPP2LPLLIPGKDM4E | |
| Hydrochloric Acid SCHEMBL3273205 | 0.77 | MAPT (0.68) | NOS1KDM4ECYP3A4MAPTPRMT6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230000878-A1 | PYRIDINE DERIVATIVES WITH N-LINKED CYCLIC SUBSTITUENTS AS cGAS INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2023-01-05 | — | — | US | disclosed |
| EP-3939658-A1 | SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORS | Biocryst Pharmaceuticals, Inc. (US) | 2022-01-19 | — | — | EP | disclosed |
| US-20140243286-A1 | BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | COFERON, INC. (US) | 2014-08-28 | — | — | US | disclosed |
| US-8314112-B2 | Pyrrolopyrimidines and pyrrolopyridines | NOVARTIS AG (CH) | 2012-11-20 | — | — | US | disclosed |
| EP-2242756-A2 | PYRROLOPYRIMIDINES AND PYRROLOPYRIDINES | Novartis AG (CH) | 2010-10-27 | — | — | EP | disclosed |
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | NOVARTIS AG (CH) | 2009-07-16 | — | — | US | disclosed |
| WO-2009087225-A2 | PYRROLOPYRIMIDINES AND PYRROLOPYRIDINES | NOVARTIS AG (CH) | 2009-07-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243286-A1 | BROMODOMAIN LIGANDS CAPABLE OF DIMERIZING IN AN AQUEOUS SOLUTION, AND METHODS OF USING SAME | BRDT, BRD4, BRD1 | ENPP2 2629/4885LPL 4309/4885LIPG 3530/4885 |
| US-20090181941-A1 | Pyrrolopyrimidines and Pyrrolopyridines | ALK, ACVR1, PTPN4 | ENPP2 366/4885LPL 2217/4885LIPG 2295/4885 |
| US-20230000878-A1 | PYRIDINE DERIVATIVES WITH N-LINKED CYCLIC SUBSTITUENTS AS cGAS INHIBITORS | CGAS, GLS2, GMPS | ENPP2 1169/4885LPL 1864/4885LIPG 2308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.